EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Survival of Colon Cancer in a Population‐Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor

Pauline Brindel iD, Evelyne Fournier iD, Pierre Olivier Chappuis iD, Thomas McKee iD, Mario Kreutzfeldt, Giacomo Puppa, Johan Ferrari, Jakob Nikolas Kather iD, Elisabetta Rapiti iD, Simone Benhamou

Cancer Medicine · 2026

DOI: 10.1002/cam4.72140 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Pauline Brindel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Geneva Cancer Registry, Institute of Global Health, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Colonic Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Krebsliga Schweiz, Ligue Genevoise Contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disparities in survival between left‐ versus right‐sided colon cancer have been reported. We studied the role of sidedness on survival of colon cancer across tumor biomarkers subgroups in a population‐based cohort established using the Geneva Cancer Registry database. Our study included 3503 colon cancer cases diagnosed between 1985 and 2013. Right‐sided colon cancers (ICD‐O codes C18.0, C18.2–18.4) and left‐sided colon cancers (ICD‐O codes C18.5–18.7) were compared. Five‐year net survival was estimated using the Pohar‐Perme estimator. Flexible hazard models evaluated the association of survival with sidedness adjusted for patient, tumor, and treatment characteristics. Left‐sided colon cancers were more frequent than right‐sided colon cancers (53% vs. 47%). Right‐sided colon cancer cases were older and more often women, less frequently of stage I or well differentiated. Left‐sided colon cancer had a higher 5‐year net survival than right‐sided colon cancer (66% vs. 59%, p < 0.001). In a multivariable model, patients with a left‐sided tumor had a 25% reduction in 5‐year mortality compared with right‐sided tumors (excess hazard ratio [eHR]: 0.75, 95% confidence interval [CI]: 0.63–0.89, p = 0.001). This association remained significant only among stage IV while not among stages I‐III. Among a subgroup of 2438 cases, stratification on tumor molecular biomarkers confirmed the better prognosis of left‐sided colon cancer versus right‐sided colon cancer among microsatellite stable (MSS) tumors, tumors with BRAF wild‐type (BRAFwt), and iCMS2 tumors. This study shows the importance of sidedness for prognosis and treatment considerations in addition to tumor biomarkers. Further research is needed to assess the molecular mechanisms underlying these differences between left and right colon cancer to address the prognostic gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsHumansFemaleMaleAgedMiddle AgedNeoplasm StagingBiomarkers, TumorPrognosisRegistriesCohort StudiesAged, 80 and overMicrosatellite InstabilityProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

biomarkerscolorectal cancermolecular oncologyregistrysurvival

Substanzen

Biomarkers, TumorProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Geneva Cancer Registry, Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Oncogenetics Unit, Division of Precision Oncology, Geneva University Hospitals, Geneva, Switzerland.
  • Division of Genetic Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Else Kroener Fresenius Center for Digital Health, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.

ORCID-Profile: Pauline Brindel, Evelyne Fournier, Pierre Olivier Chappuis, Thomas McKee, Jakob Nikolas Kather, Elisabetta Rapiti

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Krebsliga Schweiz
  • Ligue Genevoise Contre le Cancer

Zitieren

APA

Brindel, P., Fournier, E., Chappuis, P. O., McKee, T., Kreutzfeldt, M., Puppa, G., Ferrari, J., Kather, J. N., Rapiti, E., & Benhamou, S. (2026). Survival of Colon Cancer in a Population‐Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor. Cancer Medicine. https://doi.org/10.1002/cam4.72140

Vancouver

Brindel P, Fournier E, Chappuis PO, McKee T, Kreutzfeldt M, Puppa G, et al. Survival of Colon Cancer in a Population‐Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor. Cancer Medicine. 2026. doi:10.1002/cam4.72140

BibTeX
@article{Brindel2026,
  author = {Brindel, Pauline and Fournier, Evelyne and Chappuis, Pierre Olivier and McKee, Thomas and Kreutzfeldt, Mario and Puppa, Giacomo and Ferrari, Johan and Kather, Jakob Nikolas and Rapiti, Elisabetta and Benhamou, Simone},
  title = {Survival of Colon Cancer in a Population‐Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72140}
}
Kostenlos starten →